Safety and Efficacy of Dexmedetomidine (DEX) for Sedation... | NCT04237792 | Trialant
NCT04237792
Sponsor
Pfizer
Status
Completed
Last Update Posted
Nov 16, 2022Actual
Enrollment
128Actual
Phase
Phase 4
Conditions
MRI Sedation
Interventions
dexmedetomidine
propofol
Countries
United States
Japan
Protocol Section
Identification Module
NCT ID
NCT04237792
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
C0801039
Secondary IDs
Not provided
Brief Title
Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans
Official Title
A PHASE 3/4 RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY OF THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE (DEX) USED WITH PROPOFOL (PRO) AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS ≥1 MONTH TO <17 YEARS OF AGE UNDERGOING MRI SCANS
Acronym
Not provided
Organization
PfizerINDUSTRY
Status Module
Record Verification Date
Oct 2022
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Feb 18, 2020Actual
Primary Completion Date
Nov 2, 2021Actual
Completion Date
Nov 30, 2021Actual
First Submitted Date
Jan 17, 2020
First Submission Date that Met QC Criteria
Jan 17, 2020
First Posted Date
Jan 23, 2020Actual
Results Waived
Not provided
Results First Submitted Date
Oct 18, 2022
Results First Submitted that Met QC Criteria
Oct 18, 2022
Results First Posted Date
Nov 16, 2022Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Oct 18, 2022
Last Update Posted Date
Nov 16, 2022Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
PfizerINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This is a randomized, double-blind, dose-ranging study of the efficacy and safety of dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric subjects ≥1 month to <17 years of age undergoing MRI scans in the US and Japan.
Detailed Description
Not provided
Conditions Module
Conditions
MRI Sedation
Keywords
procedural sedation
dexmedetomidine
propofol
MRI
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 4
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
128Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
dexmedetomidine low dose group
Experimental
low dose of dexmedetomidine to be given
Drug: dexmedetomidine
Drug: propofol
dexmedetomidine middle dose group
Experimental
middle dose of dexmedetomidine to be given
Drug: dexmedetomidine
Drug: propofol
dexmedetomidine high dose group
Experimental
high dose of dexmedetomidine to be given
Drug: dexmedetomidine
Drug: propofol
Interventions
Name
Type
Description
Arm Group Labels
Other Names
dexmedetomidine
Drug
dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percentage of Participants at the DEX High Dose Versus Low Dose in the Combined Age Cohorts Who Did Not Require Concomitant PRO to Complete MRI
Percentage of participants who did not require PRO to complete MRI scan in the combined age cohorts are reported in this outcome measure.
Up to maximum of 3 hours during MRI scan on Day 1
Secondary Outcomes
Measure
Description
Time Frame
Percentage of Participants at the DEX High Dose Versus Low Dose in Each Age Cohort Who Did Not Require Concomitant PRO to Complete MRI
Percentage of participants who did not require PRO to complete MRI scan in each age cohort are reported in this outcome measure.
Up to maximum of 3 hours during MRI scan on Day 1
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Key Inclusion Criteria:
Male or female subject ≥1 month and <17 years of age.
American Society of Anesthesiologists (ASA) Physical Status I, II or III.
Requires non-intubated, spontaneous breathing, moderate to deep sedation (NI MDS) for a magnetic resonance imaging (MRI) study with an intensivist, anesthesiologist or other proceduralist in attendance.
Duration of the MRI scan is expected to take at least 20 minutes but no more than 3 hours to complete
Key Exclusion Criteria:
Pregnant female subjects (including those with an indeterminate or positive pregnancy test); breastfeeding female subjects.
Weight on Day 1 before randomization is less than the 10th percentile of weight for age and sex in the US and Japan or is greater than the 95th percentile of weight for age and sex in the US or greater than the 97th percentile of weight for age and sex in Japan based on sponsor-provided growth charts.
Planned medical procedure during the MRI scan or post-MRI recovery period.
Requires endotracheal intubation or laryngeal mask airway (LMA).
Known allergy to eggs, egg products, soybeans or soybean products.
SpO2 <93 % on room air -
Accepts Healthy Volunteers
No
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
1 Month
Maximum Age
16 Years
Standard Ages
Child
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Not provided
Overall Officials
Name
Affiliation
Role
Pfizer CT.gov Call Center
Pfizer
Study Director
Locations
Facility
Status
City
State
ZIP
Country
Contacts
Arkansas Children's
Little Rock
Arkansas
72202
United States
Lucile Packard Children's Hospital, Stanford
References Module
Citations
Not provided
See Also Links
Label
URL
To obtain contact information for a study center near you, click here.
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Pediatric participants were administered with dexmedetomidine (DEX), and with propofol (PRO) as needed, for procedural sedation for magnetic resonance imaging (MRI) scans.
Recruitment Details
Total 141 participants were screened. Out of 141 participants, only 128 participants who met eligibility criteria signed the informed consent document, were enrolled and randomized. Out of 128 randomized participants, 6 participants were not treated.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Low Dose: Age >=1 Month to <2 Years
Day 1: Participants aged >=1 month to <2 years, were randomized to receive a loading dose of DEX 0.5 microgram per kilogram (mcg/kg) over 10 minutes as intravenous (IV) infusion followed by continuous maintenance dose of DEX 0.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per physical investigator (PI) clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
propofol IV administration will be given if needed to maintain sedation
dexmedetomidine high dose group
dexmedetomidine low dose group
dexmedetomidine middle dose group
Percentage of Participants at the DEX Middle Dose vs Low Dose and High Dose vs Middle Dose in Each Age Cohort and Combined Age Cohorts Who Did Not Require Concomitant PRO to Complete MRI
Percentage of participants who did not require PRO to complete MRI scan in each age cohort and combined age cohorts are reported in this outcome measure.
Up to maximum of 3 hours during MRI scan on Day 1
Percentage of Time at Target Pediatric Sedation State Scale (PSSS) Score of 2 After the Administration of the DEX Loading Dose and During the DEX Maintenance Infusion - By Age Cohort and Combined Age
In this outcome measure percentage of time for which participant had maintained PSSS score of 2 was reported. PSSS score ranges from 0 to 5, where 0= sedation with abnormal physiologic parameters requiring acute intervention, 1= sedation with normal vital signs, but requiring airway intervention, 2= no movement during procedure, no frown, no verbalization of complaint indicating no pain and anxiety, 3= no movement during procedure but expression of pain and anxiety on face, verbalization of complaint, requiring help positioning, 4= movement during procedure requiring gentle immobilization for positioning, verbalization of some discomfort or stress, but no crying or shouting that expresses stress or objection, 5= movement impeding proceduralist and requiring forceful immobilization, crying or shouting during procedure, but vocalization not required. Higher score indicated less sedation.
Up to maximum of 3 hours during MRI scan on Day 1
Time From the Start of DEX Loading Dose Infusion to the Time of First PRO Bolus Infusion - By Age Cohort and Combined Age
Participants who did not have PRO administered were censored.
Up to maximum of 3 hours during MRI scan on Day 1
Emergence Time - By Age Cohort and Combined Age
Emergence time: time from the end of the MRI scan to when the participant met a Modified Aldrete score >=9. Participants who were withdrawn or discharged without reaching a Modified Aldrete score >=9, were censored, time computed from end of MRI scan to time of the last clinical assessment (vital signs). Zero minute was used as the censored time if no vital signs were taken during the post-MRI recovery period. Modified Aldrete score: validated observational medical scoring system that allowed verbal prompts for the measurement of recovery after anesthesia (post anesthesia) which included items: activity, respiration, circulation, consciousness, and oxygenation. Each item was scored from 0 to 2, higher scores signified better recovery. The scores of each item were summed to obtain a total score of 0 to 10, where higher scores indicated well recovered participant post anesthesia.
Post MRI scan on Day 1 up to 24 hours
Number of Participants Who Received PRO - By Age Cohort and Combined Age
Up to maximum of 3 hours during MRI scan on Day 1
Total Amount (mcg Per kg) of Concomitant PRO Required to Successfully Complete MRI - By Age Cohort and Combined Age
Up to maximum of 3 hours during MRI scan on Day 1
Body Weight/Time Adjusted Total Amount (Per kg Per Minute) of Concomitant PRO Required to Successfully Complete MRI - By Age Cohort and Combined Age
Up to maximum of 3 hours during MRI scan on Day 1
Palo Alto
California
94304
United States
University of California Davis Medical Center
Sacramento
California
95817
United States
Baptist Health - Wolfson Children's Hospital
Jacksonville
Florida
32207
United States
St. Mary's Medical Center
West Palm Beach
Florida
33407
United States
Children's Healthcare of Atlanta-Egleston
Atlanta
Georgia
30322
United States
IU Health Riley Hospital for Children
Indianapolis
Indiana
46202
United States
University of Michigan, C.S. Mott Children's Hospital
Ann Arbor
Michigan
48109-4245
United States
M Health Fairview University of Minnesota Medical Center - West Bank
Minneapolis
Minnesota
55454
United States
Duke University Medical Center
Durham
North Carolina
27710
United States
Brody School of Medicine at East Carolina University
Greenville
North Carolina
27834
United States
Vidant Medical Center
Greenville
North Carolina
27834
United States
University Hospitals Rainbow Babies and Children's Hospital
Cleveland
Ohio
44106
United States
The Children's Hospital at OUMC
Oklahoma City
Oklahoma
73104
United States
Children's Medical Center
Dallas
Texas
75235
United States
Texas Children's Hospital
Houston
Texas
77030
United States
Ibaraki Children Hospital
Mito
Ibaraki
311-4145
Japan
Shikoku Medical Center for Children and Adults
Zentsujichó
Kagawa-ken
765-8507
Japan
Osaka Women's and Children's Hospital
Izumi-shi
Osaka
594-1101
Japan
Shizuoka Children's Hospital
Shizuoka
Shizuoka
420 8660
Japan
Tokyo Metropolitan Children's Medical Center
Fuchū
Tokyo
183-8561
Japan
National Center for Child Health and Development
Setagaya-ku
Tokyo
157-8535
Japan
Osaka City General Hospital
Osaka
534-0021
Japan
FG001
Middle Dose: Age >=1 Month to <2 Years
Day 1: Participants aged >=1 month to <2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
FG002
High Dose: Age >=1 Month to <2 Years
Day 1: Participants aged >=1 month to <2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
FG003
Low Dose: Age >=2 Years to <17 Years
Day 1: Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 0.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
FG004
Middle Dose: Age >=2 Years to <17 Years
Day 1: Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
FG005
High Dose: Age >=2 Years to <17 Years
Day 1: Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
FG00021 subjects
FG00122 subjects
FG00220 subjects
FG00323 subjects
FG00421 subjects
FG00521 subjects
Treated With DEX
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG00421 subjects
FG00520 subjects
COMPLETED
FG00019 subjects
FG00121 subjects
FG00217 subjects
FG00322 subjects
FG00420 subjects
FG00518 subjects
NOT COMPLETED
FG0002 subjects
FG0011 subjects
FG0023 subjects
FG0031 subjects
FG0041 subjects
FG0053 subjects
Type
Comment
Reasons
Adverse Event
FG0001 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0041 subjects
FG0051 subjects
Other
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG004
Not treated
FG0001 subjects
FG0011 subjects
FG0022 subjects
FG0031 subjects
FG004
MRI Scan (Day 1)
Type
Comment
Milestone Data
STARTED
FG00020 subjectsDEX infusion could be discontinued during MRI scan, if clinically indicated.
FG00121 subjects
FG00218 subjectsDEX infusion could be discontinued during MRI scan, if clinically indicated.
FG00322 subjects
FG00421 subjectsDEX infusion could be discontinued during MRI scan, if clinically indicated.
FG00520 subjectsDEX infusion could be discontinued during MRI scan, if clinically indicated.
COMPLETED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Post MRI Scan Recovery (Day 1)
Type
Comment
Milestone Data
STARTED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG00421 subjects
FG00520 subjects
COMPLETED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Follow-up (FU) (Day 2)
Type
Comment
Milestone Data
STARTED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG00421 subjects
FG00520 subjects
COMPLETED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Long Term FU (Any Day From Day 29 to 32)
Type
Comment
Milestone Data
STARTED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG00421 subjects
FG00520 subjects
COMPLETED
FG00020 subjects
FG00121 subjects
FG00218 subjects
FG00322 subjects
FG004
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Full analysis set (FAS) included all randomized participants who received any amount of DEX.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Low Dose: Age >=1 Month to <2 Years
Day 1: Participants aged >=1 month to <2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 0.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
BG001
Middle Dose: Age >=1 Month to <2 Years
Day 1: Participants aged >=1 month to <2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
BG002
High Dose: Age >=1 Month to <2 Years
Day 1: Participants aged >=1 month to <2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
BG003
Low Dose: Age >=2 Years to <17 Years
Day 1: Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 0.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
BG004
Middle Dose: Age >=2 Years to <17 Years
Day 1: Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
BG005
High Dose: Age >=2 Years to <17 Years
Day 1: Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes as IV infusion followed by continuous maintenance dose of DEX 1.5 mcg/kg/hour IV. If an adequate level of sedation was not achieved, participants were co-administered with PRO IV per PI clinical judgment. MRI scan started on achieving an adequate sedation level. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours. Treatment PRO first bolus strength would be 500 mcg/kg and then maintenance infusion at 50 mcg/kg/min. Participants were monitored for a minimum of 1 hour after completion of MRI scan. Day 2: Participants were followed up after 24 hours (+/- 2 hours) post discontinuation of DEX. Participants had a long-term follow-up contact via phone call at 28 to 31 days post last administration of study drug.
BG006
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00020
BG00121
BG00218
BG00322
BG00421
BG00520
BG006122
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
Years
Title
Denominators
Categories
Title
Measurements
BG0000.99± 0.612
BG0010.90± 0.488
BG0020.96± 0.384
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00012
BG0019
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0004
BG0012
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0012
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percentage of Participants at the DEX High Dose Versus Low Dose in the Combined Age Cohorts Who Did Not Require Concomitant PRO to Complete MRI
Percentage of participants who did not require PRO to complete MRI scan in the combined age cohorts are reported in this outcome measure.
FAS included all randomized participants who received any amount of DEX.
Posted
Number
95% Confidence Interval
Percentage of participants
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00038
OG00142
Title
Denominators
Categories
Title
Measurements
OG00063.2(46.0 to 78.0)
OG00114.3(5.0 to 29.0)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Cochran-Mantel-Haenszel
<0.001
Odds Ratio (OR)
0.10
2-Sided
95
0.03
0.29
Other
Secondary
Percentage of Participants at the DEX High Dose Versus Low Dose in Each Age Cohort Who Did Not Require Concomitant PRO to Complete MRI
Percentage of participants who did not require PRO to complete MRI scan in each age cohort are reported in this outcome measure.
FAS included all randomized participants who received any amount of DEX.
Posted
Number
95% Confidence Interval
Percentage of participants
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
High Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=2 Years to <17 Years
Secondary
Percentage of Participants at the DEX Middle Dose vs Low Dose and High Dose vs Middle Dose in Each Age Cohort and Combined Age Cohorts Who Did Not Require Concomitant PRO to Complete MRI
Percentage of participants who did not require PRO to complete MRI scan in each age cohort and combined age cohorts are reported in this outcome measure.
FAS included all randomized participants who received any amount of DEX.
Posted
Number
Percentage of participants
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
High Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
Secondary
Percentage of Time at Target Pediatric Sedation State Scale (PSSS) Score of 2 After the Administration of the DEX Loading Dose and During the DEX Maintenance Infusion - By Age Cohort and Combined Age
In this outcome measure percentage of time for which participant had maintained PSSS score of 2 was reported. PSSS score ranges from 0 to 5, where 0= sedation with abnormal physiologic parameters requiring acute intervention, 1= sedation with normal vital signs, but requiring airway intervention, 2= no movement during procedure, no frown, no verbalization of complaint indicating no pain and anxiety, 3= no movement during procedure but expression of pain and anxiety on face, verbalization of complaint, requiring help positioning, 4= movement during procedure requiring gentle immobilization for positioning, verbalization of some discomfort or stress, but no crying or shouting that expresses stress or objection, 5= movement impeding proceduralist and requiring forceful immobilization, crying or shouting during procedure, but vocalization not required. Higher score indicated less sedation.
FAS included all randomized participants who received any amount of DEX. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
Posted
Mean
Standard Deviation
Percentage of time
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Secondary
Time From the Start of DEX Loading Dose Infusion to the Time of First PRO Bolus Infusion - By Age Cohort and Combined Age
Participants who did not have PRO administered were censored.
FAS included all randomized participants who received any amount of DEX.
Posted
Median
95% Confidence Interval
Minutes
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=1 Month to <2 Years
Secondary
Emergence Time - By Age Cohort and Combined Age
Emergence time: time from the end of the MRI scan to when the participant met a Modified Aldrete score >=9. Participants who were withdrawn or discharged without reaching a Modified Aldrete score >=9, were censored, time computed from end of MRI scan to time of the last clinical assessment (vital signs). Zero minute was used as the censored time if no vital signs were taken during the post-MRI recovery period. Modified Aldrete score: validated observational medical scoring system that allowed verbal prompts for the measurement of recovery after anesthesia (post anesthesia) which included items: activity, respiration, circulation, consciousness, and oxygenation. Each item was scored from 0 to 2, higher scores signified better recovery. The scores of each item were summed to obtain a total score of 0 to 10, where higher scores indicated well recovered participant post anesthesia.
FAS included all randomized participants who received any amount of DEX.
Posted
Median
95% Confidence Interval
Minutes
Post MRI scan on Day 1 up to 24 hours
ID
Title
Description
OG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Middle Dose: Age >=1 Month to <2 Years
Secondary
Number of Participants Who Received PRO - By Age Cohort and Combined Age
FAS included all randomized participants who received any amount of DEX.
Posted
Count of Participants
Participants
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Secondary
Total Amount (mcg Per kg) of Concomitant PRO Required to Successfully Complete MRI - By Age Cohort and Combined Age
FAS included all randomized participants who received any amount of DEX. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
Posted
Mean
Standard Deviation
mcg per kg
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=1 Month to <2 Years
Secondary
Body Weight/Time Adjusted Total Amount (Per kg Per Minute) of Concomitant PRO Required to Successfully Complete MRI - By Age Cohort and Combined Age
FAS included all randomized participants who received any amount of DEX. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.
Posted
Mean
Standard Deviation
mcg per kg per minute
Up to maximum of 3 hours during MRI scan on Day 1
ID
Title
Description
OG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=1 Month to <2 Years
Time Frame
Day 1 up to maximum of 31 days after last dose of study drug (up to maximum of 32 days)
Description
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. The safety analysis set consisted of all randomized participants who received any amount of DEX. Safety data was presented by dose level, overall (combined two age cohorts) and within each age cohort.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
0
20
0
20
19
20
EG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
0
21
0
21
20
21
EG002
High Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
0
18
0
18
17
18
EG003
Combined Dose: Age >=1 Month to <2 Years
Participants were randomized to receive a loading dose of DEX 0.5 mcg/kg (low dose), 1 mcg/kg (middle dose), and 1.5 mcg/kg (high dose) over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour (low dose), 1 mcg/kg/hour (middle dose), and 1.5 mcg/kg/hour (high dose).
0
59
0
59
56
59
EG004
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
0
22
0
22
19
22
EG005
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
0
21
0
21
19
21
EG006
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
0
20
1
20
19
20
EG007
Combined Dose: Age >=2 Years to <17 Years
Participants were randomized to receive a loading dose of DEX 0.5 mcg/kg (low dose), 1.2 mcg/kg (middle dose), and 2 mcg/kg (high dose) over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour (low dose), 1 mcg/kg/hour (middle dose), and 1.5 mcg/kg/hour (high dose).
0
63
1
63
57
63
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Hypertension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG0030 affected59 at risk
EG0040 affected22 at risk
EG0050 affected21 at risk
EG0061 affected20 at risk
EG0071 affected63 at risk
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Bradycardia
Cardiac disorders
MedDRA v24.1
Non-systematic Assessment
EG0009 affected20 at risk
EG00112 affected21 at risk
EG00213 affected18 at risk
EG00334 affected59 at risk
EG00415 affected22 at risk
EG00512 affected21 at risk
EG00614 affected20 at risk
EG00741 affected63 at risk
Rebound tachycardia
Cardiac disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Sinus arrhythmia
Cardiac disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0021 affected18 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA v24.1
Non-systematic Assessment
EG0002 affected20 at risk
EG0011 affected21 at risk
EG0020 affected18 at risk
EG003
Arnold-Chiari malformation
Congenital, familial and genetic disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Syringomyelia
Congenital, familial and genetic disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA v24.1
Non-systematic Assessment
EG0001 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA v24.1
Non-systematic Assessment
EG0001 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Anaesthetic complication neurological
Injury, poisoning and procedural complications
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0021 affected18 at risk
EG003
Contusion
Injury, poisoning and procedural complications
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0021 affected18 at risk
EG003
Blood pressure increased
Investigations
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Seizure
Nervous system disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Agitation
Psychiatric disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Bradypnoea
Respiratory, thoracic and mediastinal disorders
MedDRA v24.1
Non-systematic Assessment
EG00019 affected20 at risk
EG00116 affected21 at risk
EG00212 affected18 at risk
EG003
Hypoxia
Respiratory, thoracic and mediastinal disorders
MedDRA v24.1
Non-systematic Assessment
EG0003 affected20 at risk
EG0013 affected21 at risk
EG0020 affected18 at risk
EG003
Tachypnoea
Respiratory, thoracic and mediastinal disorders
MedDRA v24.1
Non-systematic Assessment
EG0001 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Diastolic hypertension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0001 affected20 at risk
EG0013 affected21 at risk
EG0023 affected18 at risk
EG003
Diastolic hypotension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0001 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Hypertension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0009 affected20 at risk
EG00112 affected21 at risk
EG0029 affected18 at risk
EG003
Hypotension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0009 affected20 at risk
EG0016 affected21 at risk
EG0023 affected18 at risk
EG003
Systolic hypertension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0013 affected21 at risk
EG0021 affected18 at risk
EG003
Withdrawal hypertension
Vascular disorders
MedDRA v24.1
Non-systematic Assessment
EG0000 affected20 at risk
EG0010 affected21 at risk
EG0020 affected18 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00018
OG00120
OG00220
OG00322
Title
Denominators
Categories
Title
Measurements
OG00050.0(26.0 to 74.0)
OG00115.0(3.0 to 38.0)
OG00275.0(51.0 to 91.0)
OG00313.6(3.0 to 35.0)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Mantel Haenszel
0.022
Odds Ratio (OR)
0.18
2-Sided
95
0.04
0.82
Other
OG002
OG003
Mantel Haenszel
<0.001
Odds Ratio (OR)
0.05
2-Sided
95
0.01
0.26
Other
Low Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00018
OG00121
OG00220
OG00320
OG00421
OG00522
OG00638
OG00742
OG00842
Title
Denominators
Categories
Title
Measurements
OG00050.0
OG0019.5
OG00215.0
OG00375.0
OG00461.9
OG00513.6
OG00663.2
OG00735.7
OG00814.3
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Mantel Haenszel
0.006
Odds Ratio (OR)
0.11
2-Sided
95
0.02
0.59
Other
OG001
OG002
Mantel Haenszel
0.597
Odds Ratio (OR)
1.68
2-Sided
95
0.25
11.27
Other
OG003
OG004
Mantel Haenszel
0.374
Odds Ratio (OR)
0.54
2-Sided
95
0.14
2.07
Other
OG004
OG005
Mantel Haenszel
0.001
Odds Ratio (OR)
0.10
2-Sided
95
0.02
0.44
Other
OG006
OG007
Mantel Haenszel
0.015
Odds Ratio (OR)
0.32
2-Sided
95
0.13
0.81
Other
OG007
OG008
Mantel Haenszel
0.024
Odds Ratio (OR)
0.30
2-Sided
95
0.10
0.87
Other
OG001
Middle Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00020
OG00121
OG00218
OG00322
OG00420
OG00520
OG00642
OG00741
OG00838
Title
Denominators
Categories
Title
Measurements
OG00077.5± 15.94
OG00182.5± 12.04
OG00287.8± 23.93
OG00376.8± 18.36
OG00492.2± 9.72
OG00594.1± 12.22
OG00677.2± 17.04
OG00787.2± 11.88
OG00891.1± 18.71
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG001
OG002
Wilcoxon (Mann-Whitney)
0.021
Other
OG000
OG002
Wilcoxon (Mann-Whitney)
0.007
Other
OG000
OG001
Wilcoxon (Mann-Whitney)
0.225
Other
OG004
OG005
Wilcoxon (Mann-Whitney)
0.213
Other
OG003
OG005
Wilcoxon (Mann-Whitney)
<0.001
Other
OG003
OG004
Wilcoxon (Mann-Whitney)
0.006
Other
OG007
OG008
Wilcoxon (Mann-Whitney)
0.011
Other
OG006
OG008
Wilcoxon (Mann-Whitney)
<0.001
Other
OG006
OG007
Wilcoxon (Mann-Whitney)
0.004
Other
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00020
OG00121
OG00218
OG00322
OG00421
OG00520
OG00642
OG00742
OG00838
Title
Denominators
Categories
Title
Measurements
OG00016.0(15.0 to 21.0)
OG00117.0(16.0 to 25.0)
OG00262.0(19.0 to NA)Upper value of 95 % confidence interval (CI) could not be estimated due to less number of participants with event.
OG00316.5(15.0 to 25.0)
OG004NA(31.0 to NA)Median and upper value of 95 % CI could not be estimated due to less number of participants with event.
OG005NA(72.0 to NA)Median and upper value of 95 % CI could not be estimated due to less number of participants with event.
OG00616.0(15.0 to 20.0)
OG00731.5(17.0 to 64.0)
OG008NA(45.0 to NA)Median and upper value of 95 % CI could not be estimated due to less number of participants with event.
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG001
OG002
Log Rank
0.016
Other
OG000
OG002
Log Rank
0.005
Other
OG000
OG001
Log Rank
0.368
Other
OG004
OG005
Log Rank
0.358
Other
OG003
OG005
Log Rank
0.000
Other
OG003
OG004
Log Rank
0.001
Other
OG007
OG008
Log Rank
0.020
Other
OG006
OG008
Log Rank
0.000
Other
OG006
OG007
Log Rank
0.005
Other
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG002
High Dose: Age >=1 Month to <2 Years
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00020
OG00121
OG00218
OG00322
OG00421
OG00520
OG00642
OG00742
OG00838
Title
Denominators
Categories
Title
Measurements
OG00030.0(6.0 to 59.0)
OG00141.0(34.0 to 54.0)
OG00238.0(12.0 to 51.0)
OG00335.0(21.0 to 49.0)
OG00446.0(25.0 to 64.0)
OG00550.0(35.0 to 62.0)
OG00635.0(21.0 to 41.0)
OG00742.5(35.0 to 52.0)
OG00845.5(35.0 to 54.0)
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG001
OG002
Log Rank
0.884
Other
OG000
OG002
Log Rank
0.662
Other
OG000
OG001
Log Rank
0.236
Other
OG004
OG005
Log Rank
0.733
Other
OG003
OG005
Log Rank
0.128
Other
OG003
OG004
Log Rank
0.165
Other
OG007
OG008
Log Rank
0.752
Other
OG006
OG008
Log Rank
0.139
Other
OG006
OG007
Log Rank
0.051
Other
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00020
OG00121
OG00218
OG00322
OG00421
OG00520
OG00642
OG00742
OG00838
Title
Denominators
Categories
Title
Measurements
OG00017
OG00119
OG0029
OG00319
OG0048
OG0055
OG00636
OG00727
OG00814
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
Units
Counts
Participants
OG00017
OG00119
OG0029
OG00319
OG0048
OG0055
OG00636
OG00727
OG00814
Title
Denominators
Categories
Title
Measurements
OG0004012.1± 2334.66
OG0014730.3± 3398.21
OG0022822.8± 1593.84
OG0035559.2± 4038.95
OG0045001.9± 4093.70
OG0054513.0± 4620.56
OG0064828.6± 3390.42
OG0074810.7± 3538.71
OG0083426.4± 2973.00
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG001
OG002
ANOVA
0.124
Other
OG000
OG002
ANOVA
0.186
Other
OG000
OG001
ANOVA
0.470
Other
OG004
OG005
ANOVA
0.845
Other
OG003
OG005
ANOVA
0.621
Other
OG003
OG004
ANOVA
0.747
Other
OG007
OG008
ANOVA
0.218
Other
OG006
OG008
ANOVA
0.181
Other
OG006
OG007
ANOVA
0.984
Other
Participants aged >=1 month to < 2 years, were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG003
Low Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG004
Middle Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG005
High Dose: Age >=2 Years to <17 Years
Participants aged >=2 years to <17 years, were randomized to receive a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG006
Low Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 0.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 0.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG007
Middle Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour and a loading dose of DEX 1.2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.
OG008
High Dose: Combined Age
Participants aged >=1 month to <2 years and >=2 years to <17 years were randomized to receive a loading dose of DEX 1.5 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour and a loading dose of DEX 2 mcg/kg over 10 minutes followed by maintenance dose of DEX 1.5 mcg/kg/hour respectively. If adequate sedation was not achieved PRO was co-administered. DEX and PRO (if needed) continued till completion of MRI scan. MRI scan was expected to complete in not more than 3 hours.